Literature DB >> 3391222

Psychomotor development in congenital hypothyroidism. The Greek screening programme.

F Komianou1, G Makaronis, J Lambadaridis, E Sarafidou, F Vrachni, C Mengreli, S Pantelakis.   

Abstract

In 1979 a national screening programme for congenital hypothyroidism (CH) was introduced in Greece. Treatment with L-thyroxine was started immediately after confirmation of the diagnosis, at a median age of 28 days. A standardized development test (Griffiths) was given to a group of CH infants and to healthy controls at the ages of 5-7, 11-13, 17-19, and 23-25 months. Thirty-three infants with CH were also studied at the age of 35-37 months. The mean developmental quotient of CH infants was 103.8 +/- 12.0, 100.9 +/- 10.1, 103.3 +/- 7.1 and 99.8 +/- 10.2 from the ages of 5-7 to 23-25 months, and was not statistically different from those of the controls. Statistical analysis showed no significant differences between athyreotic children and those with an ectopic gland. Our findings show that the prognosis for psychomotor development of children with CH is quite good, provided that treatment starts in the first 6 weeks of life.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391222     DOI: 10.1007/bf00442694

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  11 in total

Review 1.  The later growth of the brain and its vulnerability.

Authors:  J Dobbing
Journal:  Pediatrics       Date:  1974-01       Impact factor: 7.124

2.  Vulnerability of developing brain and behaviour.

Authors:  J Dobbing; J L Smart
Journal:  Br Med Bull       Date:  1974-05       Impact factor: 4.291

3.  Undernutrition and the developing brain. The relevance of animal models to the human problem.

Authors:  J Dobbing
Journal:  Am J Dis Child       Date:  1970-11

4.  Effects of neonatal screening for hypothyroidism: prevention of mental retardation by treatment before clinical manifestations. New England congenital hypothyroidism collaborative.

Authors: 
Journal:  Lancet       Date:  1981-11-14       Impact factor: 79.321

5.  Screening for congenital hypothyroidism: the first decade.

Authors:  N D Barnes
Journal:  Arch Dis Child       Date:  1985-06       Impact factor: 3.791

6.  Preliminary results on the mental development of hypothyroid infants detected by the Quebec Screening Program.

Authors:  J Glorieux; J H Dussault; J Letarte; H Guyda; J Morissette
Journal:  J Pediatr       Date:  1983-01       Impact factor: 4.406

7.  Neonatal screening for hypothyroidism in Greece.

Authors:  C Mengreli; K Kassiou; S Tsagaraki; S Pantelakis
Journal:  Eur J Pediatr       Date:  1981-10       Impact factor: 3.183

8.  Characteristics of infantile hypothyroidism discovered on neonatal screening.

Authors: 
Journal:  J Pediatr       Date:  1984-04       Impact factor: 4.406

9.  Neuropsychological study in treated thyroid dysgenesis.

Authors:  R Wolter; P Noël; P De Cock; M Craen; C Ernould; P Malvaux; F Verstaeten; J Simons; S Mertens; N Van Broeck; M Vanderschueren-Lodeweyckx
Journal:  Acta Paediatr Scand Suppl       Date:  1979

10.  Neurological abnormalities in patients treated for hypothyroidism from early life.

Authors:  R Macfaul; S Dorner; E M Brett; D B Grant
Journal:  Arch Dis Child       Date:  1978-08       Impact factor: 3.791

View more
  3 in total

Review 1.  Congenital hypothyroidism: optimal management in the light of 15 years' experience of screening.

Authors:  D B Grant
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

2.  Prognostic factors in the intellectual development at 7 years of age in children with congenital hypothyroidism.

Authors:  M Salerno; S Di Maio; R Militerni; A Argenziano; G Valerio; A Tenore
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

3.  Relation between biochemical severity and intelligence in early treated congenital hypothyroidism: a threshold effect.

Authors:  S L Tillotson; P W Fuggle; I Smith; A E Ades; D B Grant
Journal:  BMJ       Date:  1994-08-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.